SEOM Clinical Guideline for the Diagnosis and Treatment of Esophageal Cancer (2016)

Overview

Journal Clin Transl Oncol

Specialty Oncology

Date 2016 Dec 1

PMID 27900538

Citations 14

Authors

M Martin-Richard

R Diaz Beveridge

V Arrazubi

M Alsina

M Galan Guzman

A B Custodio

C Gomez

F L Munoz

R Pazo

F Rivera

Affiliations

Soon will be listed here.

Abstract

Esophageal cancer (EC) is an aggressive tumor that represents the 6th most common cause of cancer death worldwide. The estimated incidence in Spain is 2090 cases/year. Two main pathological subtypes exist, squamous cell carcinoma and adenocarcinoma. The main differences between them are localization and underlying factors which are the principal cause of the recent incidence changes observed in west countries. Staging techniques and treatment options which combine surgery, chemotherapy and radiotherapy, reflected the high complexity of the EC management. An undeniably multidisciplinary approach is, therefore, required. In this guide, we review the status of current diagnosis and treatment, define evidence and propose recommendations.

Citing Articles

Assessing the methodological strengths and limitations of the Spanish Society of Medical Oncology (SEOM) guidelines: a critical appraisal using AGREE II and AGREE-REX tool.

Santero M, de Mas J, Rifa B, Clavero I, Rexach I, Bonfill Cosp X Clin Transl Oncol. 2023; 26(1):85-97.

PMID: 37368198 PMC: 10761528. DOI: 10.1007/s12094-023-03219-0.

Volumetric Evaluation of Staging F-FDG PET/CT Images in Patients with Esophageal Cancer.

Karahan Sen N, Aksu A, Capa Kaya G Mol Imaging Radionucl Ther. 2022; 31(3):216-222.

PMID: 36268888 PMC: 9586008. DOI: 10.4274/mirt.galenos.2022.38980.

Penpulimab, an anti-PD1 IgG1 antibody in the treatment of advanced or metastatic upper gastrointestinal cancers.

Zheng Y, Mislang A, Coward J, Cosman R, Cooper A, Underhill C Cancer Immunol Immunother. 2022; 71(10):2371-2379.

PMID: 35165764 PMC: 10991425. DOI: 10.1007/s00262-022-03160-1.

Therapeutic Potential of PARP Inhibitors in the Treatment of Gastrointestinal Cancers.

Alhusaini A, Cannon A, Maher S, Reynolds J, Lynam-Lennon N Biomedicines. 2021; 9(8).

PMID: 34440228 PMC: 8392860. DOI: 10.3390/biomedicines9081024.

Brazilian Group of Gastrointestinal Tumours' consensus guidelines for the management of oesophageal cancer.

Rocha-Filho D, Peixoto R, Weschenfelder R, Rego J, Riechelmann R, Coutinho A Ecancermedicalscience. 2021; 15:1195.

PMID: 33889204 PMC: 8043684. DOI: 10.3332/ecancer.2021.1195.

References

Crosby T, Hurt C, Falk S, Gollins S, Mukherjee S, Staffurth J . Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial. Lancet Oncol. 2013; 14(7):627-37. DOI: 10.1016/S1470-2045(13)70136-0. View

Biere S, van Berge Henegouwen M, Maas K, Bonavina L, Rosman C, Garcia J . Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial. Lancet. 2012; 379(9829):1887-92. DOI: 10.1016/S0140-6736(12)60516-9. View

Wagner A, Grothe W, Haerting J, Kleber G, Grothey A, Fleig W . Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006; 24(18):2903-9. DOI: 10.1200/JCO.2005.05.0245. View

Wang K, Johnson A, Ali S, Klempner S, Bekaii-Saab T, Vacirca J . Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and Differences. Oncologist. 2015; 20(10):1132-9. PMC: 4591943. DOI: 10.1634/theoncologist.2015-0156. View

Van Cutsem E, Moiseyenko V, Tjulandin S, Majlis A, Constenla M, Boni C . Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006; 24(31):4991-7. DOI: 10.1200/JCO.2006.06.8429. View

Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F . Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008; 358(1):36-46. DOI: 10.1056/NEJMoa073149. View

Graham L, Wikman A . Toward improved survivorship: supportive care needs of esophageal cancer patients, a literature review. Dis Esophagus. 2015; 29(8):1081-1089. DOI: 10.1111/dote.12424. View

Forde P, Kelly R . Genomic alterations in advanced esophageal cancer may lead to subtype-specific therapies. Oncologist. 2013; 18(7):823-32. PMC: 3720637. DOI: 10.1634/theoncologist.2013-0130. View

Domper Arnal M, Ferrandez Arenas A, Lanas Arbeloa A . Esophageal cancer: Risk factors, screening and endoscopic treatment in Western and Eastern countries. World J Gastroenterol. 2015; 21(26):7933-43. PMC: 4499337. DOI: 10.3748/wjg.v21.i26.7933. View

10.

Lennerz J, Kwak E, Ackerman A, Michael M, Fox S, Bergethon K . MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol. 2011; 29(36):4803-10. PMC: 3255989. DOI: 10.1200/JCO.2011.35.4928. View

11.

Kato H, Arao T, Matsumoto K, Fujita Y, Kimura H, Hayashi H . Gene amplification of EGFR, HER2, FGFR2 and MET in esophageal squamous cell carcinoma. Int J Oncol. 2013; 42(4):1151-8. PMC: 3622677. DOI: 10.3892/ijo.2013.1830. View

12.

Thallinger C, Raderer M, Hejna M . Esophageal cancer: a critical evaluation of systemic second-line therapy. J Clin Oncol. 2011; 29(35):4709-14. DOI: 10.1200/JCO.2011.36.7599. View

13.

Markar S, Gronnier C, Duhamel A, Pasquer A, Thereaux J, Chalret du Rieu M . Salvage Surgery After Chemoradiotherapy in the Management of Esophageal Cancer: Is It a Viable Therapeutic Option?. J Clin Oncol. 2015; 33(33):3866-73. DOI: 10.1200/JCO.2014.59.9092. View

14.

Pennathur A, Zhang J, Chen H, Luketich J . The "best operation" for esophageal cancer?. Ann Thorac Surg. 2010; 89(6):S2163-7. PMC: 3769958. DOI: 10.1016/j.athoracsur.2010.03.068. View

15.

Stahl M, Stuschke M, Lehmann N, Meyer H, Walz M, Seeber S . Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol. 2005; 23(10):2310-7. DOI: 10.1200/JCO.2005.00.034. View

16.

Conroy T, Galais M, Raoul J, Bouche O, Gourgou-Bourgade S, Douillard J . Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. Lancet Oncol. 2014; 15(3):305-14. DOI: 10.1016/S1470-2045(14)70028-2. View

17.

Ajani J, Xiao L, Roth J, Hofstetter W, Walsh G, Komaki R . A phase II randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer. Ann Oncol. 2013; 24(11):2844-9. PMC: 3937600. DOI: 10.1093/annonc/mdt339. View

18.

Shapiro J, van Lanschot J, Hulshof M, van Hagen P, van Berge Henegouwen M, Wijnhoven B . Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015; 16(9):1090-1098. DOI: 10.1016/S1470-2045(15)00040-6. View

19.

Waddell T, Chau I, Cunningham D, Gonzalez D, Okines A, Frances A . Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol. 2013; 14(6):481-9. PMC: 3669518. DOI: 10.1016/S1470-2045(13)70096-2. View

20.

Mariette C, Dahan L, Mornex F, Maillard E, Thomas P, Meunier B . Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901. J Clin Oncol. 2014; 32(23):2416-22. DOI: 10.1200/JCO.2013.53.6532. View